Press ReleasesSee all
INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ -- The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) – a neutralizing antibody – in the COVID-19
- Initial agreement for 300,000 vials with potential for purchase of an additional 650,000 vials - Patients will have no out-of-pocket costs for the medication INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S.
- Revenue in the third quarter of 2020 increased 5 percent driven by volume growth of 9 percent, while on a year-to-date basis revenue increased 6 percent driven by volume growth of 12 percent. - Key growth products launched since 2014, consisting of Taltz, Trulicity, Verzenio, Jardiance,
- Jardiance (empagliflozin) reduced risk for the composite endpoint of cardiovascular death and hospitalization for heart failure, as well as serious adverse kidney outcomes, in adults with or without chronic kidney disease at baseline. The trial included people with and without diabetes -